Evidence map›Paper›PMID 35917590›Full record

ArticleJournal of the American Chemical Society2022

1,6-

Ken Kok, Chi-Lin Kuo, Rebecca E Katzy, Lindsey T Lelieveld, Liang Wu, Véronique Roig-Zamboni, Gijsbert A van der Marel, Jeroen D C Codée, Gerlind Sulzenbacher, Gideon J Davies and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. ACS central science · 2024
    Article
  8. Chemical science · 2023
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Ken KokDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.
Chi-Lin KuoDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.ORCID 0000-0003-3748-5008
Rebecca E KatzyDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.
Lindsey T LelieveldDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.
Liang WuDepartment of Chemistry, University of York, York YO10 5DD, U.K.ORCID 0000-0003-0294-7065
Véronique Roig-ZamboniArchitecture et Fonction des Macromolécules Biologiques (AFMB), CNRS, Aix-Marseille University, Marseille 13288, France.
Gijsbert A van der MarelDepartment of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.
Jeroen D C CodéeDepartment of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.ORCID 0000-0003-3531-2138
Gerlind SulzenbacherArchitecture et Fonction des Macromolécules Biologiques (AFMB), CNRS, Aix-Marseille University, Marseille 13288, France.ORCID 0000-0003-4844-2820
Gideon J DaviesDepartment of Chemistry, University of York, York YO10 5DD, U.K.ORCID 0000-0002-7343-776X
Herman S OverkleeftDepartment of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.ORCID 0000-0001-6976-7005
Johannes M F G AertsDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.ORCID 0000-0001-8168-2565
Marta ArtolaDepartment of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, The Netherlands.ORCID 0000-0002-3051-3902
Leiden University · NLCentre National de la Recherche Scientifique · FRUniversity of York · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

α-Glucosidase inhibitors are potential therapeutics for the treatment of diabetes, viral infections, and Pompe disease. Herein, we report a 1,6-

Indexed as

Glycogen Storage Disease Type IIalpha-GlucosidasesAnimalsCyclohexanolsGlucan 1,4-alpha-GlucosidaseGlycogenGlycoside Hydrolase InhibitorsHumansZebrafishalpha-GlucosidasesCyclohexanolscyclophellitolGlucan 1,4-alpha-GlucosidaseGlycogenGlycoside Hydrolase Inhibitors

Identifiers

PMID35917590
PMCPMC9389588
OpenAlexW4289521330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.